CLINICAL TRIALS PROFILE FOR DALBAVANCIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for dalbavancin hydrochloride
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00057369 ↗ | Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections | Unknown status | Vicuron Pharmaceuticals | Phase 2 | 2001-02-01 | This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin. |
NCT00678106 ↗ | Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections | Completed | Pfizer | Phase 1 | 2008-09-01 | Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalbavancin. |
NCT01339091 ↗ | Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections | Completed | Durata Therapeutics Inc., an affiliate of Allergan plc | Phase 3 | 2011-03-01 | The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial skin or skin structure infection. |
NCT01431339 ↗ | Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections | Completed | Durata Therapeutics Inc., an affiliate of Allergan plc | Phase 3 | 2011-07-01 | The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infections. |
NCT01946568 ↗ | A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years. | Completed | Durata Therapeutics Inc., an affiliate of Allergan plc | Phase 1 | 2013-06-01 | A phase one study to characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for dalbavancin hydrochloride
Condition Name
Clinical Trial Locations for dalbavancin hydrochloride
Trials by Country
Clinical Trial Progress for dalbavancin hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for dalbavancin hydrochloride
Sponsor Name